Braskem S.A. (NYSE:BAK - Get Free Report) shares reached a new 52-week low on Friday . The stock traded as low as $3.30 and last traded at $3.27, with a volume of 988379 shares. The stock had previously closed at $3.63.
Analyst Ratings Changes
Separately, Scotiabank cut shares of Braskem from a "sector outperform" rating to a "sector perform" rating in a research report on Monday, March 3rd.
Check Out Our Latest Stock Report on Braskem
Braskem Stock Up 12.5 %
The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -0.92 and a beta of 1.80. The company has a 50 day simple moving average of $4.00 and a 200-day simple moving average of $4.86.
Braskem (NYSE:BAK - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.01). The company had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.52 billion. Braskem had a negative net margin of 9.88% and a negative return on equity of 439.59%. As a group, sell-side analysts anticipate that Braskem S.A. will post -0.77 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Braskem
A number of institutional investors and hedge funds have recently made changes to their positions in BAK. Covalis Capital LLP increased its position in Braskem by 27.1% in the 4th quarter. Covalis Capital LLP now owns 1,173,852 shares of the company's stock valued at $4,531,000 after buying an additional 250,215 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Braskem by 14.3% during the fourth quarter. Marshall Wace LLP now owns 787,348 shares of the company's stock valued at $3,039,000 after acquiring an additional 98,406 shares in the last quarter. Walleye Capital LLC raised its position in shares of Braskem by 60.5% during the fourth quarter. Walleye Capital LLC now owns 512,076 shares of the company's stock worth $1,977,000 after purchasing an additional 193,120 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Braskem by 126.1% in the 4th quarter. Renaissance Technologies LLC now owns 329,910 shares of the company's stock worth $1,273,000 after purchasing an additional 184,010 shares in the last quarter. Finally, Trexquant Investment LP grew its position in Braskem by 145.8% in the 4th quarter. Trexquant Investment LP now owns 258,638 shares of the company's stock valued at $998,000 after purchasing an additional 153,401 shares during the period.
Braskem Company Profile
(
Get Free Report)
Braskem SA, together with its subsidiaries, produces and sells thermoplastic resins. The company operates through three segments: Brazil, United States and Europe, and Mexico. The Brazil segment produces and sells olefins, including ethylene, polymer and chemical grade propylene, butadiene, and butene-1; benzene, toluene, and xylenes products; fuels, such as automotive gasoline, liquefied petroleum gas, ethyl tertiary-butyl ether, and methyl tertiary-butyl ether; intermediates, such as cumene; aliphatics, aromatics, and hydrogenated solvents; and specialties comprising isoprene, dicyclopentadiene, piperylene, nonene, tetramer, polyisobutylene, and hydrocarbon resins.
See Also
Before you consider Braskem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Braskem wasn't on the list.
While Braskem currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.